Since then, extensive preclinical and clinical research has supported this hypothesis, providing compelling evidence that insulin dysregulation may not only contribute to the progression of the disease but could also be a causative factor, driving the disruption of other pathways implicated in AD (Alves et al. 2021; Kellar and Craft 2020). This evidence concerns the gene INS and Alzheimer disease.